GeneDx and Partners Secure $14.4M NIH Grant to Launch First U.S. Multi-State Genomic Newborn Screening Initiative

Reuters
2025/10/02
GeneDx and Partners Secure $14.4M NIH Grant to Launch First U.S. Multi-State Genomic Newborn Screening Initiative

**GeneDx Holdings Corp. and Partners Launch First U.S. National Genomic Newborn Screening Initiative with $14.4 Million NIH Grant** GeneDx Holdings Corp. (Nasdaq: WGS) has announced the launch of BEACONS (Building Evidence and Collaboration for GenOmics in Nationwide Newborn Screening), the nation's first multi-state genomic newborn screening initiative. The project is funded by a $14.4 million grant from the National Institutes of Health (NIH) Common Fund Venture Program, awarded jointly to multiple organizations including Mass General Brigham, Ariadne Labs, Boston Children's Hospital, Albert Einstein College of Medicine, the Association of Public Health Laboratories (APHL), Case Western Reserve University, Baylor College of Medicine, and Illumina. BEACONS will pilot the integration of whole genome sequencing into state newborn screening programs, recruiting up to 30,000 newborns across as many as 10 states over the next three years. This collaboration aims to evaluate the feasibility, ethical considerations, and potential public health impact of using genomic sequencing for newborn screening in the United States. If successful, the project could pave the way for expanding genomic screening nationwide.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genedx Holdings Corp. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251001487540) on October 01, 2025, and is solely responsible for the information contained therein.

应版权方要求,你需要登录查看该内容

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10